Form 4: Atara Biotherapeutics CEO Sells Shares for Tax Obligations

Atara Biotherapeutics' President and CEO, AnhCo Nguyen, sold 2,915 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• AnhCo Nguyen, President and CEO and Director of Atara Biotherapeutics, Inc. (ATRA), reported a sale of common stock.
• The transactions occurred on November 17, 2025.
• A total of 2,915 shares were sold in two separate transactions: 2,859 shares at $13.186 and 56 shares at $13.188.
• The sales were executed automatically to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units.
• These sales were conducted under a pre-arranged Rule 10b5-1(c) plan.
• Following these transactions, AnhCo Nguyen beneficially owns 64,974 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine, non-discretionary sale to cover tax obligations related to executive compensation, which is a common and expected event and does not reflect a change in management's outlook on the company.

Positives

• The sale was non-discretionary, executed automatically to cover tax withholding obligations, which is a routine event for executive compensation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale rather than a reaction to new information.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, could be perceived negatively by some investors.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries, particularly in biotechnology where executive compensation often includes significant equity components. It does not directly reflect broader industry trends or specific company performance beyond the mechanics of executive compensation.

Comparison to Industry Standards

• This is a standard 'sale-to-cover' transaction, a common practice for executives across publicly traded companies when restricted stock units vest.
• The execution under a Rule 10b5-1(c) plan aligns with typical executive compensation and tax planning strategies, demonstrating a pre-planned, non-discretionary sale.

Related Party Transactions

• The reported transaction is a sale of common stock by a key executive (AnhCo Nguyen), which is a related party transaction, executed to satisfy tax withholding obligations.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a routine tax purpose, so likely minimal impact on investor sentiment.
• Employees: The filing mentions the sale was on behalf of a group of employees, suggesting similar tax-related sales might occur for other employees with vesting restricted stock units.

Key Dates

Recommendation

The sale of shares by the President and CEO was an automatic transaction to satisfy tax withholding obligations upon the vesting of restricted stock units, executed under a pre-arranged Rule 10b5-1(c) plan. This is a common and expected event for executive compensation and does not reflect a discretionary decision by management regarding the company's future prospects. Therefore, it does not provide new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, AnhCo Nguyen, Biotechnology